News & Updates
Filter by Specialty:
Severe COVID-19 rare in PrEP-treated SARDs patients
08 Mar 2024
byStephen Padilla
Breakthrough COVID-19 is not uncommon following pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs), reports a recent study. However, most of the infections in this high-risk population are not severe.